Evicenter
Opdivo (nivolumab) in Metastatic non-small cell lung cancer
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Opdivo (opens in a new tab)
Questions
60
Last updated

All questions

Safety: Opdivo (nivolumab) in metastatic non-small cell lung cancer

8 questions · 6 sources

Side effects

What are common side effects of Opdivo plus Yervoy in lung cancer?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

What serious side effects occurred with Opdivo plus Yervoy in Checkmate 227?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

What are common side effects of Opdivo, Yervoy, and chemo (Checkmate 9LA)?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

What serious side effects occurred with Opdivo, Yervoy, and chemotherapy (Checkmate 9LA)?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

What are the side effects of Opdivo in previously treated NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

What side effects did Opdivo Qvantig cause in Checkmate 67T (kidney cancer)?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

Note: Checkmate 67T enrolled adults with advanced or metastatic clear cell renal cell carcinoma; the safety page for previously treated metastatic NSCLC presents these data.

How common is pneumonitis with Opdivo plus Yervoy in NSCLC?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Administration reactions

Can Opdivo cause infusion reactions?